期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 13, 期 7, 页码 1293-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2015.02.017
关键词
Thiopurines; Infliximab; Adalimumab; Surgery; Hospitalization; Infection
资金
- AHRQ [R01-HS018517]
- [NIHK24-DK078228]
- [K08 DK084347]
BACKGROUND & AIMS: The benefit of continuing immunomodulators when stepping up to anti-tumor necrosis factor (anti-TNF) therapy for Crohn's disease (CD) is uncertain. This study assessed the effectiveness and safety of immunomodulators with anti-TNF therapy in CD. METHODS: We conducted a retrospective cohort study of new users of anti-TNF therapy for CD in Medicare. Users of anti-TNF combination therapy with immunomodulators were matched to up to 3 users of anti-TNF monotherapy via propensity score and compared by using 3 metrics of effectiveness surgery, hospitalization, and discontinuation of anti-TNF therapy or surgery and 2 metrics of safety serious infection and non-Candida opportunistic infection. Cox regression was used for all analyses. RESULTS: Among new users of infliximab, we matched 381 users of combination therapy to 912 users of monotherapy; among new users of adalimumab, we matched 196 users of combination therapy to 505 users of monotherapy. Combination therapy occurred predominantly as step up after thiopurine therapy. The rates of surgery (hazard ratio [Hit], 1.20; 95% confidence interval, 0.73-1.96), hospitalization (HR, 0.82; 0.57-1.19), discontinuation of anti-TNF therapy or surgery (HR, 1.09; 0.88-1.34), and serious infection (HR, 0.93; 0.88-1.34) did not differ between users of anti-TNF combination therapy and monotherapy. However, the risks of opportunistic infection (HR, 2.64; 1.21-5.73) and herpes zoster (HR, 3.16; 1.25-7.97) were increased with combination therapy. CONCLUSIONS: We found that continuation of immunomodulators after stepping up to anti-TNF therapy did not improve outcomes but was associated with an increased risk of opportunistic infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据